Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

442 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Patent Strategies For Protecting Synthetic Biology Inventions

    In Synthetic biology researchers actively design biological components to create new configurations that may include generating biofuels, production of medical biomolecules, synthetic gene networks for sensing or diagnostics, and more .
    IndiaFood, Drugs, Healthcare, Life Sciences
    Aumirah
    Aumirah
  • Article

    Patents On Healthcare Products (Video)

    A healthcare product is often defined as a service to research, innovate, procure, sell and deliver better means of health welfare to everyone.
    IndiaIntellectual Property
    Photon legal
    Photon legal
Article

Artificial Intelligence In The Pharma Industry

Artificial intelligence (AI) is driving a transformative wave in the pharmaceutical and biotechnology sectors. Its integration into drug discovery, diagnostics, and clinical trials...
IndiaFood, Drugs, Healthcare, Life Sciences
De Penning & De Penning
De Penning & De Penning
  • Article

    Healthcare Sector's Expectation From Budget 2023

    As we enter 2023, the world is recovering from the pandemic and is well on its way to reaching pre-pandemic level normalcy. India is no different and has recovered swiftly in 2022...
    IndiaFood, Drugs, Healthcare, Life Sciences
    Nexdigm Private Limited
    Nexdigm Private Limited
  • Article

    Medical Devices- A Perspective & The Medical Devices (Amendment) Rules, 2020

    Before any rules were notified for medical devices, they were being governed solely by the dated and redundant Drugs and Cosmetics Act, 1940 with no specific provisions or aspects pertaining to the regulation of medical devices in India.
    IndiaFood, Drugs, Healthcare, Life Sciences
    AMLEGALS
    AMLEGALS
  • Article

    The Permissibility Paradox: Regulatory Dissonance Between The UCMPMD And The IMC Regulations

    The regulation of interactions between the healthcare industry and healthcare professionals has historically occupied a sensitive intersection between commercial freedom, professional ethics, patient welfare, and public trust. In India, this balancing exercise has recently assumed renewed significance following the amendment dated April 30, 2026 (“Amendment”) to the Uniform Code for Marketing Practices in Medical Devices, 2024 (“UCMPMD”), whereby medical device companies have now been permitted to extend travel and hospitality facilities to healthcare professionals serving as speakers at Continuing Medical Education (“CME”) or Continuing Professional Development (“CPD”) programmes, or as participants in training programmes
    IndiaFood, Drugs, Healthcare, Life Sciences
    Luthra and Luthra Law Offices India
    Luthra and Luthra Law Offices India
  • Article

    New Rules Governing Corporate Social Responsibility

    On January 22, 2021, the Government of India brought into effect the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2021 ("Rules").
    IndiaCorporate/Commercial Law
    Obhan Mason
    Obhan Mason
  • Article

    CDSCO’s Market Interventions And The New Compliance Framework For Pharma And Cosmetic Operations

    India's life sciences, pharmaceutical, and consumer healthcare sectors are entering a more enforcement-driven regulatory phase. Recent interventions by the Central Government, the Central Drugs Standard Control...
    IndiaFood, Drugs, Healthcare, Life Sciences
    Lakshmikumaran & Sridharan
    Lakshmikumaran & Sridharan
  • Article

    Draft Compensation Formula For Clinical Trial Related Injury Proposed

    DCGI has published a draft formula for calculating compensation payable to a clinical trial participant when the subject suffers an injury owing to his or her participation.
    IndiaFood, Drugs, Healthcare, Life Sciences
    Nishith Desai Associates
    Nishith Desai Associates
  • Article

    Is 'Combination Invention' An 'Old Wine In A New Bottle'?

    Using a combination of known elements to create a new invention is an age-old practice to stay ahead in competition.
    IndiaIntellectual Property
    Lex Orbis
    Lex Orbis
  • Article

    A New Code For Pharmaceutical Marketing Practices: From Symptoms To Diagnosis

    The New Code applies to both pharmaceutical and medical device companies.
    IndiaFood, Drugs, Healthcare, Life Sciences
    S&R Associates
    S&R Associates
  • Article

    E- Pharmacy In India (Ban Or No Ban)

    It cannot be debated that E-pharmacy cannot be equated with normal e-commerce platform.
    IndiaFood, Drugs, Healthcare, Life Sciences
    Khurana & Khurana, Advocates and IP Attorneys
    Khurana & Khurana, Advocates and IP Attorneys
  • Article

    JSA Newsletter | Healthcare | September And October 2024 Edition

    This edition of the JSA healthcare newsletter focuses on the key developments undertaken in the Indian healthcare ecosystem in September and October 2024. Some of the major developments include introduction.
    IndiaFood, Drugs, Healthcare, Life Sciences
    JSA Advocates & Solicitors
    JSA Advocates & Solicitors
  • Article

    The Digital Health And Medical Device Revolution In India

    The landscape of the Indian healthcare industry is in constant flux, with new developments taking place on an almost daily basis in terms of both technology and law.
    IndiaFood, Drugs, Healthcare, Life Sciences
    Nishith Desai Associates
    Nishith Desai Associates
  • Article

    The India-UK FTA And The Life Sciences Sector: A New Era For Pharmaceuticals, Biotechnology And Healthcare Innovation?

    The recently concluded India–UK Comprehensive Economic and Trade Agreement (CETA) has generated significant interest across sectors ranging from automobiles and textiles to professional services.
    IndiaFood, Drugs, Healthcare, Life Sciences
    King, Stubb & Kasiva
    King, Stubb & Kasiva
  • Article

    Reaffirming Standards: Bioavailability V. Therapeutic Efficacy And Coverage V. Disclosure

    In India, patent applications filed for new forms of known chemical entities have always faced strict scrutiny under the provisions of Section 3(d) of the Indian Patents Act, 1970 (‘Act').
    IndiaIntellectual Property
    Lakshmikumaran & Sridharan
    Lakshmikumaran & Sridharan
  • Article

    Revision Of MRP Post GST 2.0 Reforms: MRP Labelling Norms For FMCG And Pharma Sectors

    In response to the recent Goods and Services Tax (‘GST') 2.0 reforms, the government has issued important clarifications to guide stakeholders...
    IndiaTax
    Lakshmikumaran & Sridharan
    Lakshmikumaran & Sridharan
  • Article

    Checking The Pulse Legal Developments In The Indian Healthcare And Pharma Sector

    Martin Luther King Junior famously said, "Of all the forms of inequality, injustice in health is the most shocking and inhumane." Echoing this assertion, in the recently concluded...
    IndiaFood, Drugs, Healthcare, Life Sciences
    CMS INDUSLAW
    CMS INDUSLAW
  • Article

    Medical Devices Rules: Faster Manufacturing Licence Approvals

    The Union Ministry of Health and Family Welfare (the “Ministry”) has recently published a Draft Notification[1] in the Official Gazette proposing amendments to the Medical Devices Rules, 2017[2] (the “Rules”), promulgated under the Drugs and Cosmetics Act, 1940. The proposed amendments specifically target the statutory timelines prescribed for processing manufacturing licence applications across the four risk-based classifications of medical devices.
    IndiaFood, Drugs, Healthcare, Life Sciences
    S.S. Rana & Co.
    S.S. Rana & Co.
  • Article

    Arbitration As A Cure For Pharmaceutical Disputes

    Pharmaceutical disputes, being the largest and fastest-growing business sectors in the world are increasingly being settled through international arbitration, particularly in the context of ...
    IndiaLitigation, Mediation & Arbitration
    Luthra and Luthra Law Offices India
    Luthra and Luthra Law Offices India
  • Showing 321–340 of 442 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics